Yes, the company's future financing plan is correct. It's contingent on clinical success of course; there will be debt financing available if needed, and will be cheaper. I suspect we over issued equity.
Once Anavex is certain of future revenue, borrowing money could still be cheaper than dilutive financing. Probably the current inflationary environment will have changed before Anavex gets that far.
Cost of debt would be 5-6%, which is 3-4% after tax. Cost of equity for a small cap stock is approximately 20%.
Debt is VASTLY CHEAPER, inflation or not. Especially when inflation rate is far higher than interest rate....in essence you get paid to borrow.
But only to build out production and distribution after approval.
At that point, banks will be begging us to borrow.
News 
Market Data 
Discover 
AI
